

ASX RELEASE

ASX Code: ESE

10 August 2021

Delisting from ASX

eSense-Lab Limited (ASX: ESE) (“eSense” or the “Company”) advises that on Friday, 6 August 2021, shareholders of the Company passed a special resolution to delist the Company from the Official List of the ASX (**Delisting**).

As the Company’s securities are not readily able to be traded, the usual condition that the removal of an entity must not take place any earlier than one month after security holder approval has been obtained, has not been imposed, on the basis that the Company’s securities are suspended from official quotation. The Delisting will therefore occur today, 10 August 2021, at close of trading Sydney time.

Following the Delisting, holders of CHESS Depository Interests (**CDIs**) (**CDI Holders**) will have their CDIs converted to the underlying Ordinary Shares in the Company, in accordance with the following process and indicative timetable.

Event	Date ¹
Delisting Date (at close of trading, Sydney time)	10 August 2021
ASX Settlement to give notice of its decision to revoke approval of the CDIs	11 August 2021
Any CHESS CDI holdings to be converted to the Issuer Sponsored register (CHESS Holdings Conversion) ²	17 August 2021
CHESS Depository Nominees Pty Ltd (CDN) to revoke the trust under which it holds Ordinary Shares (CDN Revocation)	18 August 2021
Notice to be sent to CDI Holders stating that: <ul style="list-style-type: none"> approval of CDIs has been revoked by ASX Settlement; CDN has revoked the trust under which it holds the Ordinary Shares (and the effective date of the revocation of the trust); and the CDI Holders’ CHESS CDI holdings have been converted to the Issuer Sponsored register. 	Promptly following CDN Revocation
CDN to transfer the title to the underlying Ordinary Shares to the former CDI Holder (Transfer of Title) and Company to cancel remaining CDIs	Promptly following CHESS Holdings Conversion
Company to issue to former CDI Holders Issuer Sponsored Holding Statements in respect of Ordinary Shares	Within 5 Business Days of Transfer of Title

1. Dates and times above are Sydney, Australia time and are indicative only and subject to change by the Company or ASX.

2. This will occur automatically, 5 Business Days after the Delisting Date.



The Company is not undertaking a share sale facility or other facility for CDI Holders or shareholders to dispose of their CDIs or the underlying shares in the Company. Security holders who wish to sell their securities will need to find a buyer for their securities and complete a standard off-market transfer form, and provide it to the Company's share registry for processing.

Refer to the Company's Notice of Meeting released on 1 July 2021 and ASX announcement released on 25 June 2021, for further information.

Following the Delisting, the Company will endeavour to provide updates on its website from time to time, will engage with Shareholders at its annual general meeting, and will post or email any information required to be sent to Shareholders in the manner and time periods required by Israeli Companies Law. Shareholders may contact the Company via the contact details available on the Company's website.

This announcement has been authorised by the Board of Directors of eSense.

Ends

For further information, please contact:

Investor enquiries

Chief Executive Officer
Yoav Elishoov
+972 8 6453934

About eSense-Lab | Registered office: Suite 5 CPC, 145 Stirling Highway, Nedlands, WA, Australia, 6009

eSense-Lab Ltd is a life sciences company creating virtual plant-based products for medicinal and recreational consumption. Headquartered in Israel, eSense-Lab combines genetics, mRNA expression, phytochemical characterisation and unique formulations to generate comprehensive models of rare or high value plants. With multi-disciplinary research and development expertise, eSense has game-changing techniques and unique reverse-engineering capabilities, placing it at forefront of the growing international terpene market. eSense has created virtual cannabis, with all the characteristics of the real plant, without the psychoactive and heavily regulated cannabinoid compound, for mass consumer consumption. To learn more, please visit www.esense-lab.com.

